Eye Disease Archives

News and Trends 11 Oct 2017

French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic

Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops gene therapies to treat genetic diseases affecting vision. The company will now start a Phase I/II clinical trial that will recruit 12 patients at the Nantes […]

October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Jul 2017

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […]

July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […]

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 May 2017

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic and fibrotic diseases and cancer. Now the company has cleared its first Phase I trial for its lead candidate ISTH0036 in […]

May 15, 2017 - 2 minutesmins - By Melanie De Almeida

Interview 11 May 2017

Video: Meet the CEO developing Gene Therapy without Viral Vectors

Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […]

May 11, 2017 - 2 minutesmins - By Melanie De Almeida

Eyevensis Eye Gene Therapy Approval France

News and Trends 11 Apr 2017

France Approves Trials for the First Eye Gene Therapy Free of Viral DNA

Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared by the French Product Security Regulatory Agency (ANSM) to proceed into the clinic with its EyeCET platform. The company is developing this gene therapy platform […]

April 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2016

Meet one of the Most Impressive French Biotech Entrepreneurs

The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons and takeaways. Here are the major ones. You might have seen Bernard Gilly’s name in the […]

November 14, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 24 Oct 2016

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jul 2016

French Startup raised €4M for Gene Therapy to fix specific Types of Blindness

Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M in its Series A round, which will speed up development of two candidates. Eye disorders are a popular indication for gene therapies, especially after the first gene therapy approvals – uniQure’s Glybera and GSK’s Strimvelis. Some other players in ophthalmologic […]

July 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jun 2016

Novel Bionic Vision device gains approval for clinical trials in Renowned UK Hospital

Pixium Vision will be testing its new IRIS II bionic vision system in a clinical trial. The device can mimic eye function in people affected by Retinitis pigmentosa and Macular degeneration. Based in Paris (France), Pixium Vision is developing an alternative for people who have lost their sight – a bionic vision restoration system (VRS). One […]

June 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eye Disease

French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Video: Meet the CEO developing Gene Therapy without Viral Vectors

France Approves Trials for the First Eye Gene Therapy Free of Viral DNA

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Meet one of the Most Impressive French Biotech Entrepreneurs

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

French Startup raised €4M for Gene Therapy to fix specific Types of Blindness

Novel Bionic Vision device gains approval for clinical trials in Renowned UK Hospital

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!